



Please join us
for the upcoming
virtual meeting

To register, please email:
cherriejuanyin.tam@biogen.com

Time to SHINE on SMA

Long-term outcomes in infants and
children participating in SHINE,
the nusinersen open-label extension study

Faculty



Diana Castro, MD

Associate Professor of Pediatrics, Neurology, and Neurotherapeutics
University of Texas Southwestern Medical Center
Dallas, TX, USA



Thomas Crawford, MD

Co-Director of MDA Clinic for Neuromuscular Disorders and Ataxia
Telangiectasia Clinical Center
Johns Hopkins Hospital
Baltimore, MD, USA

Agenda

The nusinersen clinical development program

Angela Paradis, ScD

Biogen

Treatment outcomes in patients with infantile-onset SMA
who met the permanent ventilation endpoint

Applying the evidence from ENDEAR-SHINE

Diana Castro, MD

Treatment outcomes in older patients with later-onset SMA

Applying the evidence from CHERISH-SHINE

Thomas Crawford, MD



Please join us
for the upcoming
virtual meeting

To register, please email:
cherriejuanyin.tam@biogen.com

Time to SHINE on SMA

Exploring the evidence from SHINE,
the nusinersen open-label extension study
in infants and children

Faculty



Francesco Muntoni, MD, FRCPH, FMedSci

Director of the Dubowitz Neuromuscular Centre
UCL Great Ormond Street Institute of Child Health and
Great Ormond Street Hospital for Children
London, UK



Andrés Nascimento, MD

Department of Neurology, Neuromuscular Unit
Hospital Sant Joan de Déu
Barcelona, Spain

Agenda

The nusinersen clinical development programme

Angela Paradis, ScD

Biogen

Setting treatment expectations in infantile-onset SMA

Applying the evidence from ENDEAR-SHINE

Francesco Muntoni, MD, FRCPH, FMedSci

Setting treatment expectations in later-onset SMA

Applying the evidence from CHERISH-SHINE

Andrés Nascimento, MD